TASMAR Drug Patent Profile
✉ Email this page to a colleague
When do Tasmar patents expire, and when can generic versions of Tasmar launch?
Tasmar is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in TASMAR is tolcapone. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tolcapone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tasmar
A generic version of TASMAR was approved as tolcapone by NOVAST LABS on August 7th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TASMAR?
- What are the global sales for TASMAR?
- What is Average Wholesale Price for TASMAR?
Summary for TASMAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 108 |
| Clinical Trials: | 19 |
| Patent Applications: | 5,522 |
| Drug Prices: | Drug price information for TASMAR |
| What excipients (inactive ingredients) are in TASMAR? | TASMAR excipients list |
| DailyMed Link: | TASMAR at DailyMed |
Recent Clinical Trials for TASMAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Chicago | Phase 2 |
| University of Colorado, Denver | Phase 2 |
| Corino Therapeutics, Inc. | Early Phase 1 |
Pharmacology for TASMAR
| Drug Class | Catechol-O-Methyltransferase Inhibitor |
| Mechanism of Action | Catechol O-Methyltransferase Inhibitors |
US Patents and Regulatory Information for TASMAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TASMAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for TASMAR
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Viatris Healthcare Limited | Tasmar | tolcapone | EMEA/H/C/000132 Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. |
Authorised | no | no | no | 1997-08-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TASMAR
See the table below for patents covering TASMAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0237929 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | ⤷ Sign Up |
| New Zealand | 219496 | PYROCATECHOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
| Latvia | 5742 | 3,5-Divaizvietoti pirokatehina atvasinajumi | ⤷ Sign Up |
| Luxembourg | 90219 | ⤷ Sign Up | |
| South Korea | 930001337 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TASMAR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0237929 | 68/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827 |
| 0237929 | 97C0112 | Belgium | ⤷ Sign Up | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 19970827 |
| 0237929 | C970041 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TOLCAPON; REGISTRATION NO/DATE: EU/1/97/044/001-6 19970827 |
| 0237929 | SPC/GB97/088 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
